AVACLYR

PeakSM

acyclovir

NDAOPHTHALMICOINTMENT
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

DNA Polymerase Inhibitors

Pharmacologic Class:

Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor

Indications (2)

the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1HSV-2) virus

Clinical Trials (5)

NCT05098938Phase 3Completed

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

Started Nov 2021
2,020 enrolled
Recurrent Herpes Labialis
NCT04988646N/ACompleted

Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject

Started Feb 2020
NCT04664127N/ACompleted

Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel

Started Oct 2017
NCT03073967Phase 3Completed

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Started May 2017
NCT01453075Phase 1Completed

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

Started Nov 2011
31 enrolled
Chronic Hepatitis C Infection
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers